Skip to content

Study · Non-randomized trial · n = 52 · 2021

4 results

Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study.

Duck L, Demolin G, D'Hondt L, Dopchie C, Hendrickx K, Lannoye B, Bastin F, Lossignol D, Hamdan O, Lybaert W, Vandenhaute V, Regnault B, De Ruyter V, Geboes K

Clinical therapeutics26 Nov 2021Cited by 3 (Europe PMC)

PMID34844770 (opens in a new tab)DOI10.1016/j.clinthera.2021.10.014 (opens in a new tab)PepBankPUB-34844770
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In malignant intestinal obstruction, lanreotide response was 24/52 (46.2%), exceeding the 30% reference proportion (P = 0.0055).

    In plain wordsIn malignant intestinal obstruction, 46.2% responded to lanreotide, exceeding the 30% reference proportion.

    Peptide
    Lanreotide
    Outcome
    IncreaseResponse before or at day 7
    Study

    n = 52

    Comparator
    reference proportion of 30%
    Analysis
    Primary
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg · deep subcutaneous injectionAs given in this study (human).

    Measurements

    Responders
    24 patients
    intention-to-treat population, of 52 patients
    Response proportion
    46.2%
    intention-to-treat population; reference proportion 30%
    p value
    0.0055
    response proportion vs reference proportion of 30%

    Source sentences

    Summary
    The proportion of responders in the intention-to-treat population was 24 of 52 (46.2%), which was significantly greater than the reference proportion of 30% (P = 0.0055).
    2 context sentences
    Summary · context
    The primary end point was the percentage of responding patients before or at day 7. Response was defined as ≤2 vomiting episodes per day (for patients without NGT at baseline) or no vomiting recurrence (after NGT removal) during at least 3 consecutive days at any time point between treatment and day 7.
    Summary · context
    This single-arm, multicenter study enrolled 52 patients mostly with advanced gastrointestinal or ovarian malignant tumors (35 patients with NGT and 17 patients without NGT). Patients received 1 deep subcutaneous injection of LAN 120 mg.
  2. 02HumanNon-randomized trialEfficacy outcome

    After lanreotide for malignant intestinal obstruction, median time to response was 9 days overall.

    In plain wordsAfter lanreotide for malignant intestinal obstruction, median time to response was 9 days overall.

    Peptide
    Lanreotide
    Outcome
    Not applicableTime to response overall
    Study

    n = 52

    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg · deep subcutaneous injectionAs given in this study (human).

    Measurements

    Median time to response
    9 days
    overall population

    Source sentences

    Summary
    Median time to response was 9 days for the overall population, 3 days for patients without NGT, and 14 days for patients with NGT (P < 0.0001).
    1 context sentence
    Summary · context
    This single-arm, multicenter study enrolled 52 patients mostly with advanced gastrointestinal or ovarian malignant tumors (35 patients with NGT and 17 patients without NGT). Patients received 1 deep subcutaneous injection of LAN 120 mg.
  3. 03HumanObservational studyEfficacy outcome

    After lanreotide for malignant intestinal obstruction, response was 88.2% without a nasogastric tube versus 25.7% with a tube.

    In plain wordsAfter lanreotide for malignant intestinal obstruction, response was 88.2% without a stomach tube versus 25.7% with a tube.

    Peptide
    Lanreotide
    Outcome
    IncreaseResponse by baseline nasogastric tube status
    Study

    n = 52

    Comparator
    patients with nasogastric tube
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg · deep subcutaneous injectionAs given in this study (human).

    Measurements

    Response proportion
    88.2%
    patients without NGT
    Response proportion
    25.7%
    patients with NGT

    Source sentences

    Summary
    Patients without NGT had a higher response (88.2%) than patients with NGT (25.7%) and had a steady trend for clinical improvement that led to sustainable responses.
    1 context sentence
    Summary · context
    This single-arm, multicenter study enrolled 52 patients mostly with advanced gastrointestinal or ovarian malignant tumors (35 patients with NGT and 17 patients without NGT). Patients received 1 deep subcutaneous injection of LAN 120 mg.
  4. 04HumanObservational studyEfficacy outcome

    After lanreotide, median time to response was 3 days without a nasogastric tube versus 14 days with a tube (P < 0.0001).

    In plain wordsAfter lanreotide, median response time was 3 days without a stomach tube versus 14 days with a tube.

    Peptide
    Lanreotide
    Outcome
    DecreaseTime to response without nasogastric tube
    Study

    n = 52

    Comparator
    patients with nasogastric tube
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    120 mg · deep subcutaneous injectionAs given in this study (human).

    Measurements

    Median time to response
    3 days
    patients without NGT
    Median time to response
    14 days
    patients with NGT
    p value
    < 0.0001
    time to response, without vs with NGT

    Source sentences

    Summary
    Median time to response was 9 days for the overall population, 3 days for patients without NGT, and 14 days for patients with NGT (P < 0.0001).
    1 context sentence
    Summary · context
    This single-arm, multicenter study enrolled 52 patients mostly with advanced gastrointestinal or ovarian malignant tumors (35 patients with NGT and 17 patients without NGT). Patients received 1 deep subcutaneous injection of LAN 120 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02275338

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Ipsenn = 5219 Nov 2014 to 9 Nov 2017

Intestinal Obstruction

Trial pageClinicalTrials.govUpdated 16 Apr 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.